DOXYCYCLINE HYCLATE ( DrugBank: Doxycycline )

3 diseases

ID	Disease name (Link within this page)	Number of trials
23	Prion disease	1
96	Crohn disease	1
227	Osler disease	1

23. Prion disease

Clinical trials : 4 / Drugs : 5 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-022233-28-IT (EUCTR)	20/06/2011	05/03/2012		Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individuals	Subjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: BASSADO INN or Proposed INN: DOXYCYCLINE HYCLATE	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-001137-99-GB (EUCTR)	28/04/2009	27/11/2008	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	Crohn's Disease MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders	Product Name: Ciprofloxacin Product Code: PL 20532/0012 INN or Proposed INN: Ciprofloxacin hydrochloride Product Name: Budesonide Product Code: PL 17901/0122 INN or Proposed INN: Budesonide Other descriptive name: Entocort CR Trade Name: DOXYCYCLINE Product Name: DOXYCYCLINE INN or Proposed INN: DOXYCYCLINE HYCLATE Other descriptive name: DOXYCYCLINE Trade Name: HYDROXYCHLOROQUINE Product Name: HYDROXYCHLOROQUINE SULPHATE INN or Proposed INN: HYDROXYCHLOROQUINE SULPHATE Other descriptive name: PLAQUENIL	Royal Liverpool & Broadgreen University Hospitals Trust	University of Liverpool	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

227. Osler disease

Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03397004 (ClinicalTrials.gov)	September 12, 2018	21/11/2017	Doxycycline for Hereditary Hemorrhagic Telangiectasia	Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia	Hereditary Hemorrhagic Telangiectasia (HHT)	Drug: Doxycycline Hyclate;Drug: Placebo	Unity Health Toronto	Barrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences Centre	Active, not recruiting	18 Years	N/A	All	30	Phase 2	Canada